Charles River Laboratories International, Inc. (NYSE:CRL) Position Reduced by Bank of Montreal Can

Bank of Montreal Can reduced its stake in shares of Charles River Laboratories International, Inc. (NYSE:CRL) by 4.5% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 43,197 shares of the medical research company’s stock after selling 2,032 shares during the period. Bank of Montreal Can owned about 0.08% of Charles River Laboratories International worth $7,974,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently modified their holdings of the company. Versant Capital Management Inc grew its stake in Charles River Laboratories International by 1,071.4% in the fourth quarter. Versant Capital Management Inc now owns 164 shares of the medical research company’s stock worth $30,000 after purchasing an additional 150 shares in the last quarter. Pinnacle Bancorp Inc. grew its position in shares of Charles River Laboratories International by 52.0% in the 4th quarter. Pinnacle Bancorp Inc. now owns 190 shares of the medical research company’s stock worth $35,000 after acquiring an additional 65 shares in the last quarter. Pilgrim Partners Asia Pte Ltd bought a new stake in shares of Charles River Laboratories International in the 4th quarter valued at approximately $48,000. Tortoise Investment Management LLC raised its position in shares of Charles River Laboratories International by 77.7% during the 4th quarter. Tortoise Investment Management LLC now owns 263 shares of the medical research company’s stock valued at $49,000 after acquiring an additional 115 shares in the last quarter. Finally, Huntington National Bank lifted its stake in Charles River Laboratories International by 120.6% during the fourth quarter. Huntington National Bank now owns 300 shares of the medical research company’s stock worth $55,000 after purchasing an additional 164 shares during the last quarter. Institutional investors own 98.91% of the company’s stock.

Insiders Place Their Bets

In other Charles River Laboratories International news, COO Birgit Girshick acquired 1,514 shares of the stock in a transaction dated Thursday, February 20th. The shares were bought at an average price of $164.63 per share, with a total value of $249,249.82. Following the purchase, the chief operating officer now directly owns 55,058 shares of the company’s stock, valued at approximately $9,064,198.54. This trade represents a 2.83 % increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, EVP Joseph W. Laplume sold 4,400 shares of the stock in a transaction that occurred on Thursday, February 20th. The shares were sold at an average price of $162.50, for a total transaction of $715,000.00. Following the sale, the executive vice president now directly owns 20,013 shares of the company’s stock, valued at approximately $3,252,112.50. This represents a 18.02 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 1.30% of the stock is owned by company insiders.

Wall Street Analysts Forecast Growth

A number of analysts have weighed in on the stock. William Blair cut shares of Charles River Laboratories International from an “outperform” rating to a “market perform” rating in a report on Wednesday, January 22nd. Citigroup raised shares of Charles River Laboratories International from a “sell” rating to a “neutral” rating and raised their target price for the stock from $155.00 to $175.00 in a report on Tuesday, March 4th. Redburn Atlantic raised Charles River Laboratories International from a “sell” rating to a “neutral” rating and set a $188.00 target price for the company in a report on Monday, March 3rd. The Goldman Sachs Group downgraded Charles River Laboratories International from a “buy” rating to a “neutral” rating and cut their price target for the stock from $190.00 to $170.00 in a report on Friday, March 21st. Finally, Morgan Stanley lowered their price objective on Charles River Laboratories International from $220.00 to $184.00 and set an “equal weight” rating for the company in a research note on Wednesday, February 5th. One research analyst has rated the stock with a sell rating and sixteen have given a hold rating to the company’s stock. According to MarketBeat, the company has an average rating of “Hold” and a consensus target price of $182.00.

Charles River Laboratories International Trading Down 0.4 %

Shares of NYSE:CRL opened at $99.56 on Monday. Charles River Laboratories International, Inc. has a twelve month low of $91.86 and a twelve month high of $254.15. The company has a current ratio of 1.41, a quick ratio of 1.14 and a debt-to-equity ratio of 0.65. The firm has a market cap of $4.89 billion, a P/E ratio of 663.71, a P/E/G ratio of 4.54 and a beta of 1.45. The company has a 50 day moving average of $156.71 and a 200-day moving average of $176.86.

Charles River Laboratories International (NYSE:CRL) last issued its quarterly earnings results on Wednesday, February 19th. The medical research company reported $2.66 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.50 by $0.16. Charles River Laboratories International had a return on equity of 14.69% and a net margin of 0.52%. The firm had revenue of $1 billion during the quarter, compared to analyst estimates of $983.63 million. During the same period last year, the company posted $2.46 EPS. The firm’s quarterly revenue was down 1.1% on a year-over-year basis. As a group, analysts anticipate that Charles River Laboratories International, Inc. will post 9.36 earnings per share for the current fiscal year.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).